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lines of Polish Agency for Health Technology Assessment. RESULTS: As a result of
a systematic search of publications, one single-blind, randomized clinical trial
(Flowers 2008), fulfilling the predefined inclusion criteria, was found. The trial di-
rectly compared the clinical effectiveness of extracorporeal photopheresis com-
bined with conventional therapy vs conventional therapy alone in the treatment of
cutaneous cGvHD that could not be controlled by steroids. Moreover, there were
identified 45 non-randomised, single-arm clinical trials which assessed the clinical
effectiveness of ECP in analysed indications. Based on identified clinical trials it
could be concluded that there is clinically relevant response to ECP treatment
among patients with acute or chronic GvHD. The highest improvement was ob-
served in skin, liver and gut among patients with aGvHD and in skin but also in
mucosa, liver and lungs involvement among patients with cGvHD. Moreover, it was
showed that ECP treatment is connected with reduction in the use of immunosup-
pressant (mainly steroids) in both groups of patients: with acute or chronic steroid-
refractory or steroid-dependant GvHD. The reduction in steroid dose allows to
reduces the risk of life-threatening bacterial, viral and fungal infections. ECP is very
well tolerated procedure. Infrequent adverse events are usually mild and seldom
led to discontinuation of the treatment. CONCLUSIONS: Results obtained from
clinical trials included in the systematic review showed that there exists clinical
benefit associated with the use of ECP in the treatment of pediatric and adult
patients with steroid-refractory, steroid-dependant acute or chronic GvHD.
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OBJECTIVES: To evaluate real-world effectiveness and device complication out-
comes of the LAP-BAND AP® System adjustable gastric band (LAGB) one year after
surgical implantation. METHODS: HERO study is a 5-year registry of 1,106 severely
or morbidly obese subjects from 29 centers in North America, Europe, and Australia
implanted with LAGB. In the current analyses, the mean change in body mass
index (BMI) and percentage excess weight loss (%EWL) at 1 year are determined.
Rates of device complication events as well surgical revisions and explants at 1 year
are also reported. RESULTS: The mean age of subjects was 43.1 years and females
constituted 79.3%. The mean(SD) weight and BMI at baseline was 126.2(24.1) kg and
45.1(6.9) kg/m2 respectively. At 1 year, the mean (SD) BMI decreased by 7.7(4.4)
kg/m2 and the average(SD) %EWL was 39.8(22.3)%. One (0.1%) death occurred from
liver cancer and was deemed not related to the device. Of 47 subjects with 53 device
complication events at 1 year, 18 (1.6%) experienced an event at 3-months, 9 (0.8%)
at 6-months, and 20 (1.8%) at 1-year. Subjects who reported device complications
were port displacement (1.8%), pouch dilatation (0.8%), band erosion (0.5%), device-
related infection (0.5%), band slippage (0.4%), port leak (0.1%), and both band slip-
page and pouch dilatation (0.3%). Eighteen (1.6%) subjects had explants and 3 (0.3%)
had the LAGB surgically revised and replaced. The indications for explants in-
cluded band erosion, band slippage, band intolerance, esophageal dilatation,
pouch dilatation, device-related infection, abdominal pain, dysphagia, and small
bowel obstruction. Minor device related revisions included access port revision
23(2.1%) and reposition of LAGB 4(0.4%). CONCLUSIONS: LAGB was associated with
significant weight loss, with less than 2% of subjects undergoing explantation of
the device within year 1 of this 5-year on-going study. Many reported device com-
plications were considered to be non-serious and could be corrected in an outpa-
tient setting.
MEDICAL DEVICE/DIAGNOSTICS - Cost Studies
PMD9
A COMPARATIVE ASSESSMENT OF COST IMPLICATIONS OF NOVEL DRUG
VERSUS NOVEL DEVICE-BASED TREATMENTS FOR STROKE PREVENTION IN
ATRIAL FIBRILLATION
Armstrong S1, Amorosi S2, Peppa R3, Da Deppo L4, Garfield S1
1GfK Bridgehead, Wayland, MA, USA, 2Boston Scientific, Natick, MA, USA, 3Boston Scientific,
Genova, Italy, 4Boston Scientific, Milan, Italy
OBJECTIVES:After decades of warfarin as the dominant strategy for stroke preven-
tion in atrial fibrillation (SPAF), new treatments are available. These include new
pharmaceuticals like dabigatran etexilate and a device based approach, left atrial
appendage closure (LAAC). Studies have compared the economics of pharmaceu-
tical treatments, but the cost implications of the device-based approach with high
initial procedural costs compared to these new drugs, with high annual costs for
life, have not been demonstrated. This analysis compares overall costs of SPAF
with LAAC to dabigatran 110mg twice daily.METHODS:An Excel-based cost impact
model was developed using data from PROTECT-AF (Holmes 2009) and RE-LY clin-
ical trial (Connelly 2009), both of which evaluated patients with a CHADS2 score1.
These studies reported similar rates of adverse events, with the exception of bleed-
ing events which were more frequent in dabigatran patients. The model captures
all costs associated with treatment, discontinuation of care and complications.
Costs were based on the German system, using published DRGs and tariffs associ-
ated with procedures, drugs, and disability care. RESULTS: First year average per
patient cost of LAAC was €11,076 compared to €3,251 for dabigatran. However, the
overall cost of care at 5 years for LAAC (€13,547) was less than dabigatran (€13,675)
due to higher annual drug and complication costs in the dabigatran arm.
CONCLUSIONS: Although LAAC was higher cost than dabigatran in the first year,
the total cost of care for dabigatran increased substantially each year, compared to
only modest annual costs for LAAC past the first year. The full burden of costs
associated with dabigatran is higher than with LAAC after five years and continues
to accrue due to high regular annual costs. This is an important consideration for
budget holders in evaluating lifetime treatment when many AF patients are now
living into their eighties and beyond.
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OBJECTIVES: Major practice changes require both clinical and economic rationale,
especially where a novel device replaces an established pharmaceutical therapy.
Recent studies have reported the clinical benefits of percutaneous left atrial ap-
pendage closure (LAAC) for stroke prevention in atrial fibrillation (SPAF) as com-
pared to standard warfarin anticoagulation, but the cost implications of the device-
based approach have not yet been demonstrated. This analysis highlights the
ongoing costs of complications associated with a long standing pharmaceutical
therapy compared to a device-based approach. METHODS: An Excel-based cost
impact model was developed using data from the PROTECT-AF clinical trial which
randomized 707 AF patients to either LAAC or warfarin (Holmes 2009). The model
captured the costs of complications in AF, including strokes, systemic embolism,
major extracranial bleeding and complications associated with the LAAC proce-
dure. Costs for stroke included only the acute, direct costs and did not capture the
long-term societal costs associated with disability. Germany, which recently rec-
ognized the LAAC procedure with a unique DRG code, was the basis for costs, using
published DRGs and tariffs associated with procedures, drugs, and care. RESULTS:
The high rate of adverse events in the warfarin arm generated €6,414 in medical
costs for complications per patient at 5 years, compared to €3,276 for LAAC. These
included mean costs of €3,239 for stroke and systemic embolism and €970 for major
bleeding in the warfarin arm, compared to €1,551 and €484 respectively for LAAC.
The mean annual cost of complications for warfarin was roughly twice that of
LAAC, (€1,283 versus €655). CONCLUSIONS: The complication cost differential
highlights the need for decision makers to consider the totality of long-term costs
and clinical implications of lifetime treatment strategies for SPAF.
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OBJECTIVES: To model the financial impact for the health care institution of spec-
imen rejection due to preanalytical errors in the laboratory testing phase, using
institution specific data. METHODS: Critical data such as number of beds; overall
budget; number of patients of different types seen each year; and number of sam-
ple rejections, as well as qualitative data, eg. probable impact of sample rejection
were collected by interviewing institution staff from multiple country institutions
(N10). The data were then entered into a model to calculate the possible financial
impact of laboratory sample rejections. The model separates patients into different
groups according to the likely effects of having a sample rejected, the probability
that the rejection would have a low, medium or high impact and the consequences
on institution time and resources. The overall consequence, or opportunity cost,
was expressed as patient treatment time and financial cost. RESULTS: The size of
the institutions ranged from 326 to 1,200 beds, with total operating costs varying
between €41 million and €1.1 billion. The number of blood tests per month was
between 37,000 and 458,000 and of these between 0.09% and 2% were rejected
(mean 0.93%). The total cost of specimen rejection ranged from €22k to €5.9 million
per annum (mean €1.9 million), equating to a percentage of total operating costs
from 0.1% to 1.2% (mean 0.4%). The estimated cost per patient for a sample rejec-
tion was from €29 to €349 (mean €171). CONCLUSIONS: A customisable model
allows institutions to estimate, using local data and assumptions, the effect of
sample rejection on patient treatment and cost. Results can be compared to those
from other institutions to benchmark performance and assumptions. The results
demonstrated that a reduction in the number of rejected samples due to preana-
lytical errors could lead to significant cost savings for most institutions.
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OBJECTIVES: Needlestick injuries (NSIs) represent a significant clinical and eco-
nomic burden to health care systems and society. The EU Directive on the preven-
tion of sharps injuries recommends adherence to a range of safety measures, of
which providing safety-engineered devices (SEDs) forms a key part. An economic
model was constructed to investigate the potential hospital budget savings asso-
ciated with the use of SEDs rather than conventional (i.e. non-safety-engineered)
devices when conducting procedures with sharp devices. METHODS: An inci-
dence-based, deterministic budget impact model with a five-year time horizon was
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